Discovery of a first-in-class EZH2 selective degrader-Reference-Cited by-同舟云学术

Discovery of a first-in-class EZH2 selective degrader

Published:2019-12-09 Issue:2 Volume:16 Page:214-222
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Ma Anqi,Stratikopoulos Elias,Park Kwang-Su,Wei Jieli,Martin Tiphaine C.,Yang Xiaobao,Schwarz Megan,Leshchenko Violetta,Rialdi Alexander,Dale Brandon^ORCID,Lagana Alessandro,Guccione Ernesto,Parekh Samir,Parsons Ramon^ORCID,Jin Jian^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41589-019-0421-4.pdf

Reference58 articles.

1. Cao, R. et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298, 1039–1043 (2002).

2. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein. Genes Dev. 16, 2893–2905 (2002).

3. Margueron, R. & Reinberg, D. The polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).

4. Kim, K. H. & Roberts, C. W. M. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).

5. Kaniskan, H. Ü., Martini, M. L. & Jin, J. Inhibitors of protein methyltransferases and demethylases. Chem. Rev. 118, 989–1068 (2018).

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

2. Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction;Chinese Medical Journal;2024-08-28

3. EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth;Oncogene;2024-08-07

4. NEUROD1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs;Frontiers in Cell and Developmental Biology;2024-07-22

5. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16